Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 1997

View Archived Issues

Gull Laboratories reports year-end and fourth-quarter results

Medtronic reports quarterly earnings up 20.8%

SmithKline Beecham reports strong growth for 1996, fueled by success of new products

T Cell Sciences reports 1996 fourth-quarter and year-end financial results

Unimed reports 1996 results: Earnings exceed published estimates

RCT discloses compounds for radiolabeling leukocytes/lymphocytes

Takeda describes antitumor agents

Antiarrhythmic agents reported by National Science Council

TK inhibitors disclosed by Pfizer

Cephalosporin antibiotics revealed by Microcide

Zeneca reports cell adhesion inhibitors

Novel class of immunosuppressants disclosed by Novartis

Comparative efficacy and tolerance of s.c. and i.m. Puregon

Dorzolamide and timolol alone and in combination for glaucoma

Sustained-release methylphenidate for HIV-associated cognitive impairment

Pramlintide delays gastric emptying in IDDM

Gamma-hydroxybutyrate associated with dependence liability

First launch for troglitazone

Celgene receives patent for selective cytokine-inhibitory drugs

Faulding receives approval for etodolac tablets

Teva's Tolmetin approved

Watson and Oclassen merge

Vyrex and SeqWright collaborate to develop CD-Tagging technology

ViroPharma receives milestone payment from Boehringer Ingelheim

Roche's Roferon-A receives EU approval

Hemagen's CMV diagnostic cleared for marketing

FDA advisory committee decision regarding Integrilin

ONYX expands ONYX-015 clinical trials

ViroPharma's antiviral candidate enters pediatric clinical trials

Advisory committee to review supplemental NDA for Maxipime

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 20, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Aug. 20, 2025.
CSL to shave off 3,000 jobs, Seqirus vaccine unit
BioWorld
CSL Ltd.’s stock tumbled 16.88% on the news that it plans to cut 3,000 jobs and to hive off its Seqirus vaccine unit in a cost-cutting measure to save more than...
Subtyping beats a path toward precision medicine in Alzheimer’s
BioWorld MedTech
Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding subtypes in Alzheimer’s disease is all...
Marvel Biotechnology’s MB-204 as therapeutic agent for Alzheimer’s disease
BioWorld Science
Phosphorylation of the protein Tau is a key post-translational feature in tauopathies like Alzheimer’s disease (AD), which leads to microtubule dysfunction and...